Metasztatikus ER+ HER2- férfi emlorák fulvestant és CKD 4/6 inhibitor palbociclib kezelésae többszörös megelozo kemoterápia, endokrin terápia és molekuláris célzott terápia utá
- Conditions
- MedDRA version: 17.0Level: LLTClassification code 10006191Term: Breast cancer male NOSSystem Organ Class: 100000004864
- Registration Number
- EUCTR2014-004226-18-HU
- Lead Sponsor
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ Onkotrápiás Klinika
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does the combination of fulvestrant and palbociclib synergistically target ER and CDK4/6 pathways in metastatic male ER+ HER2- breast cancer?
What is the comparative efficacy of fulvestrant plus palbociclib versus aromatase inhibitors in male ER+ HER2- breast cancer with prior endocrine resistance?
Which biomarkers predict response to fulvestrant and palbociclib in male ER+ HER2- breast cancer patients post-multiple therapies?
What are the safety profiles and management strategies for CDK4/6 inhibitor-related adverse events in male breast cancer patients?
What alternative CDK4/6 inhibitors or endocrine therapies are being studied in combination for metastatic male ER+ HER2- breast cancer beyond EUCTR2014-004226-18-HU?